Search

Your search keyword '"Olivier, Kenneth R."' showing total 208 results

Search Constraints

Start Over You searched for: Author "Olivier, Kenneth R." Remove constraint Author: "Olivier, Kenneth R." Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
208 results on '"Olivier, Kenneth R."'

Search Results

1. Assessment of minimum target dose as a predictor of local failure after spine SBRT

2. Sublobar Resection, Stereotactic Body Radiation Therapy, and Percutaneous Ablation Provide Comparable Outcomes for Lung Metastasis-Directed Therapy

3. Cardiopulmonary Toxicity Following Intensity-Modulated Proton Therapy (IMPT) Versus Intensity-Modulated Radiation Therapy (IMRT) for Stage III Non-Small Cell Lung Cancer

5. Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer

6. Dosimetric predictors of pneumonitis in locally advanced non-small cell lung cancer patients treated with chemoradiation followed by durvalumab

7. Development and Internal Validation of a Recursive Partitioning Analysis–Based Model Predictive of Pain Flare Incidence After Spine Stereotactic Body Radiation Therapy

9. Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer

10. Patterns of Recurrence and Modes of Progression After Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate Cancer

11. Sublobar Resection, Stereotactic Body Radiation Therapy, and Percutaneous Ablation Provide Comparable Outcomes for Lung Metastasis-Directed Therapy

12. A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer: NRG Oncology RTOG 0915 (NCCTG N0927)

17. Society for Women in Radiation Oncology Consensus Statement on Family and Medical Leave

21. Data from PD-1 Restrains Radiotherapy-Induced Abscopal Effect

22. Supplementary Table 1 from Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET/CT–Identified Oligometastatic Castration-Resistant Prostate Cancer

23. Supplementary Figure 1 from Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET/CT–Identified Oligometastatic Castration-Resistant Prostate Cancer

24. Supplementary Figure 3 from Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET/CT–Identified Oligometastatic Castration-Resistant Prostate Cancer

25. Supplementary Table 2 from Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET/CT–Identified Oligometastatic Castration-Resistant Prostate Cancer

26. Development and validation of a unifying pre-treatment decision tool for intracranial and extracranial metastasis-directed radiotherapy

27. Establishment of practice standards in nomenclature and prescription to enable construction of software and databases for knowledge-based practice review

32. Development and validation of a recursive partitioning analysis–based pretreatment decision‐making tool identifying ideal candidates for spine stereotactic body radiation therapy

33. Single and Multifraction Spine Stereotactic Body Radiation Therapy and the Risk of Radiation Induced Myelopathy

38. Stereotactic Body Radiation Therapy for Metastases in Long Bones

39. Development and validation of a recursive partitioning analysis–based pretreatment decision‐making tool identifying ideal candidates for spine stereotactic body radiation therapy.

40. Development and Assessment of a Predictive Score for Vertebral Compression Fracture After Stereotactic Body Radiation Therapy for Spinal Metastases

41. Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET/CT–Identified Oligometastatic Castration-Resistant Prostate Cancer

44. Single institution toxicity of definitive chemoradiation and maintenance durvalumab in locally advanced non-small cell lung cancer.

45. Ablative radiotherapy for ultracentral lung cancers: Dosimetric, geometric, and volumetric predictors of outcomes and toxicity

48. Association of tumor genomic factors and efficacy for metastasis-directed stereotactic body radiotherapy for oligometastatic colorectal cancer

49. Empowering Residents into Independent Practice: A Single-Institutional Endeavor Aimed at Developing Resident Autonomy Through Implementation of a Chief Resident Service in Radiation Oncology

50. Surgery for Mesothelioma After Radiation Therapy (SMART); A Single Institution Experience

Catalog

Books, media, physical & digital resources